Literature DB >> 11108934

Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors.

M Stangel1, A Compston.   

Abstract

Controlled trials in multiple sclerosis (MS) and case reports in acute demyelinating encephalomyelitis (ADEM) have shown that intravenous immunoglobulins (IVIg) are of therapeutic benefit in central nervous system (CNS) inflammatory diseases. Studies in experimental autoimmune encephalomyelitis (EAE) have suggested these effects are mediated by modulation of the cytokine network and T cell responses. However, there are no data on the influence of IVIg on the local immune reaction in the CNS, the site of inflammation in EAE. We have therefore studied the effect of IVIg on cultured rat microglia, the main immune cell in the CNS. IVIg increased nitric oxide (NO) production in a dose-dependent manner in microglia stimulated with IFNgamma. The increase was only marginal in LPS-treated cells, and no effect was seen in untreated microglia or after stimulation with TNFalpha or PMA. This enhancement of NO production depended on the Fc portion of IVIg and could be abrogated by the pharmacological inhibition of Syk and phosphatidylinositol 3-kinase, two enzymes involved in the signalling cascade of Fc receptors. TNFalpha secretion was dose-dependently stimulated by IVIg in both untreated microglia and after stimulation with LPS or IFNgamma. Again, this effect was mediated through the Fc portion. Finally, we showed that Fc receptor-mediated phagocytosis was inhibited by IVIg, presumably by blockade of the Fc receptor. These different effects may protect oligodendrocytes from antibody mediated phagocytosis and on the other hand could terminate the immune reaction by induction of apoptosis in infiltrating T cells via NO and TNFalpha. We propose that IVIg, in addition to known effects on the peripheral immune system, may also modulate the local immune reaction in CNS inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11108934     DOI: 10.1016/s0165-5728(00)00412-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

Review 1.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 2.  Can polyclonal intravenous immunoglobulin limit cytokine mediated cerebral damage and chronic lung disease in preterm infants?

Authors:  P V Mohan; W Tarnow-Mordi; B Stenson; P Brocklehurst; K Haque; V Cavendish; A Cust
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-01       Impact factor: 5.747

Review 3.  Microglia biology in health and disease.

Authors:  Gwenn A Garden; Thomas Möller
Journal:  J Neuroimmune Pharmacol       Date:  2006-03-25       Impact factor: 4.147

4.  Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity.

Authors:  Refik Pul; Darius Moharregh-Khiabani; Jelena Škuljec; Thomas Skripuletz; Niklas Garde; Elke Verena Voss; Martin Stangel
Journal:  J Neuroimmune Pharmacol       Date:  2010-11-03       Impact factor: 4.147

5.  Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses.

Authors:  Marta Feldmesser; Aron Mednick; Arturo Casadevall
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

Review 6.  Immunoglobulin-mediated neuro-cognitive impairment: new data and a comprehensive review.

Authors:  Assaf Menachem; Joab Chapman; Yael Deri; Chaim G Pick; Aviva Katzav
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

7.  Influenza virus- and cytokine-immunoreactive cells in the murine olfactory and central autonomic nervous systems before and after illness onset.

Authors:  Victor H Leyva-Grado; Lynn Churchill; Melissa Wu; Timothy J Williams; Ping Taishi; Jeannine A Majde; James M Krueger
Journal:  J Neuroimmunol       Date:  2009-05-01       Impact factor: 3.478

8.  Dose-dependent inhibition of demyelination and microglia activation by IVIG.

Authors:  Meike Winter; Christine Baksmeier; Julia Steckel; Sumanta Barman; Manish Malviya; Melanie Harrer-Kuster; Hans-Peter Hartung; Norbert Goebels
Journal:  Ann Clin Transl Neurol       Date:  2016-09-23       Impact factor: 4.511

9.  Clinical presentation and immunological features of Post-Malaria Neurologic Syndrome: a case report and review of literature.

Authors:  Nadia Castaldo; Carlo Tascini; Paola Della Siega; Maddalena Peghin; Davide Pecori
Journal:  Malar J       Date:  2020-11-23       Impact factor: 2.979

10.  Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease.

Authors:  Isabelle St-Amour; Mélanie Bousquet; Isabelle Paré; Janelle Drouin-Ouellet; Francesca Cicchetti; Renée Bazin; Frédéric Calon
Journal:  J Neuroinflammation       Date:  2012-10-09       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.